cholestyramine resin has been researched along with elobixibat in 2 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (elobixibat) | Trials (elobixibat) | Recent Studies (post-2010) (elobixibat) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 35 | 9 | 34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Ozaki, A; Saigusa, Y; Saito, S; Usuda, H; Wada, K; Yamamoto, K; Yamanaka, T; Yoneda, M | 1 |
| Honda, Y; Imajo, K; Iwaki, M; Kasai, Y; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tanaka, K; Usuda, H; Wada, K; Yoneda, M | 1 |
2 other study(ies) available for cholestyramine resin and elobixibat
| Article | Year |
|---|---|
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Topics: Adult; Cholestyramine Resin; Clinical Trials, Phase II as Topic; Dipeptides; Double-Blind Method; Humans; Non-alcoholic Fatty Liver Disease; Proof of Concept Study; Randomized Controlled Trials as Topic; Thiazepines | 2020 |
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Carcinogenesis; Cholestyramine Resin; Disease Models, Animal; Mice; Non-alcoholic Fatty Liver Disease | 2023 |